Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3921 Target Snapshot

Heparanase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
448Compounds
69Assays
0Approved Drugs
610.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Heparanase shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y251. Start with hepatocellular carcinoma, then reuse UniProt Q9Y251 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hepatocellular carcinoma, then reuse UniProt Q9Y251 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
hepatocellular carcinoma

Heparanase shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hepatocellular carcinoma because it currently carries late clinical support. Linked drugs include MUPARFOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Heparanase as ChEMBL target CHEMBL3921, mapped to UniProt Q9Y251. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Heparanase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3921
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y251
Heparanase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Heparanase is the right protein anchor across sources, using UniProt Q9Y251 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hepatocellular carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHeparanase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ9Y251
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHeparanase
UniProt AccessionQ9Y251
Component TypeProtein
Sequence Length543 aa

Heparanase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Heparanase, mapped to UniProt Q9Y251. Sequence length is 543 aa.

Mapped IDQ9Y251
Review nameHeparanase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Heparanase shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase I
cutaneous melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase I
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hepatocellular carcinoma because it currently carries late clinical support. Linked drugs include MUPARFOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehepatocellular carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
Assay Mix

Activity Type Distribution

IC50541.0
KI32.0
KD37.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2059500 8.43 Ki 3.7 Preclinical
CHEMBL2059243 8.26 Ki 5.5 Preclinical
CHEMBL2059241 8.24 Ki 5.8 Preclinical
CHEMBL2059242 8.22 Ki 6.0 Preclinical
CHEMBL5279386 8.22 Ki 6.0 Preclinical
CHEMBL2059499 8.21 Ki 6.1 Preclinical
CHEMBL2059245 8.19 Ki 6.4 Preclinical
CHEMBL2059498 8.08 Ki 8.4 Preclinical
CHEMBL2059246 8.07 Ki 8.5 Preclinical
CHEMBL2059503 8.04 Ki 9.1 Preclinical
Distribution

pChEMBL Value Distribution

79
5.0
132
5.5
143
6.0
63
6.5
11
7.0
17
7.5
11
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

70
Total Assays
400
Tested Compounds
1
Assay Types
Binding — 70 assays, 400 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 40 260 5.9
cell-based format 16 34 6.6
assay format 13 66 5.8
organism-based format 1 40 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine